This stock is positioned perfectly for 184% profits

You are receiving this as part of your free subscription to Money Morning Stock VQScore™. To remove your email from this list, unsubscribe here.

Click here to access your top-25 ranked stocks! September 28, 2019 Dear VQScore Member, The stars have aligned in your favor. Not only have we found a little-known small cap with a promising allergy treatment that could be a lifesaver for 1.6 million children and teens in America... ... but we've also found a way to play it for triple-digit gains while no one else is looking. You see, most investors will wait until January to get in on this company, when the FDA is scheduled to make its final decision on the new drug. Big mistake. Should the FDA approve the drug as expected, those investors will likely be left high and dry as the long-term shareholders take profits on the positive news. According to America's No. 1 Pattern Trader, Tom Gentile, the best time to get in on this company is now,while shares are inexpensive. In fact, with his specific trading strategy, you could double your money before the FDA even comes to a decision. The last time he recommended a trade like this, his readers had the chance to pocket 183.7% profits in just 10 days. Just click here to see the stock and Tom's play, and you'll automatically be signed up for his Power Profit Trades updates. That way, you'll get all of his recommendations the moment he releases them. Sincerely, Kyle Anderson Head of VQ Research Unsubscribe from Money Morning Stock VQScore™ Manage Your Email Preferences You are receiving this e-mail at its028@gmail.com as a part of your free subscription to the Money Morning Stock VQScore™. To read our privacy policy click here. To cancel by mail or for any other subscription issues, write us at: Money Morning Stock VQScore™ | Attn: Member Services | 1125 N. Charles Street | Baltimore, MD 21201 North America: 888.384.8339; International: 443.353.4519; Fax: 410.622.3050 Contact Customer Service Website: https://moneymorning.com © 2019 Money Morning Stock VQScore™ All Rights Reserved. Nothing in this email should be considered personalized financial advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. We expressly forbid our writers from having a financial interest in any security recommended to our readers. All of our employees and agents must wait 24 hours after on-line publication or 72 hours after the mailing of printed-only publication prior to following an initial recommendation. Any recommendations in this letter should be made only after consulting with your financial adviser and only after reviewing the prospectus or financial statements of the company. Protected by copyright laws of the United States and international treaties. This Newsletter may only be used pursuant to the subscription agreement and any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of: Money Morning Stock VQScore™. 1125 N. Charles Street, Baltimore MD 21201.